CAR-modified T-cell therapy for cancer: an updated review

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 6, 2016, Pages 1339-1349

  Haji Fatahaliha, Mostafa ^a,b,c   Hosseini, Maryam ^b,c   Akbarian, Asiye ^d   Sadreddini, Sanam ^a,b,c   Jadidi Niaragh, Farhad ^d   Yousefi, Mehdi ^a,b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer; chimeric antigen receptor; clinical studies; immunotherapy; T cells

Indexed keywords

ACTIVATION ANALYSIS; ANTIGENS; BINS; CELLS; CHEMOTHERAPY; CYTOLOGY; DISEASES; T-CELLS; TUMORS;

ANTIGEN RECEPTORS; CANCER; CANCER IMMUNOTHERAPY; CLINICAL STUDY; GENETICALLY MODIFIED; HEMATOLOGICAL MALIGNANCIES; IMMUNOTHERAPY; TRANS-MEMBRANE DOMAINS;

CELL SIGNALING;

CHIMERIC ANTIGEN RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CLINICAL TRIAL (TOPIC); HEMATOLOGIC MALIGNANCY; HUMAN; INTRACELLULAR SIGNALING; LYMPHOCYTE MIGRATION; LYMPHOCYTOPOIESIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ADOPTIVE TRANSFER; ANIMAL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROCEDURES;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS;

EID: 84982986786     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2015.1052465     Document Type: Review

References (129)

1. M.Ahmed, N.-K.V.Cheung. 2013. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 588:288–297.
2. E.J.Beecham, Q.Ma, R.Ripley, R.P.Junghans. 2000. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules:the dynamics of T-cell proliferation and death. J Immunother. 23:631–642.
3. C.M.Bollard, C.Rössig, M.J.Calonge, M.H.Huls, H.-J.Wagner, J.Massague,. 2002. Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity. Blood. 99:3179–3187.
4. L.Borkner, A.Kaiser, W.Van De Kasteele, R.Andreesen, A.Mackensen, J.B.Haanen,. 2010. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother. 59:1173–1183.
5. J.B.Brayer, J.Pinilla-Ibarz. 2013. Developing strategies in the immunotherapy of leukemias. Cancer Control. 20:49–59.
6. R.J.Brentjens, I.Rivière, J.H.Park, M.L.Davila, X.Wang, J.Stefanski,. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118:4817–4828.
7. R.J.Brentjens, E.Santos, Y.Nikhamin, R.Yeh, M.Matsushita, K.La Perle,. 2007. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 13:5426–5435.
8. P.A.Bretscher. 1999. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA. 96:185–190.
9. T.Brocker. 2000. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 96:1999–2001.
10. A.Burks, M.A.Calderon, T.Casale, L.Cox, P.Demoly, M.Jutel,. 2013. Update on allergy immunotherapy:American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 131:1288–1296.e3.
11. C.Carpenito, M.C.Milone, R.Hassan, J.C.Simonet, M.Lakhal, M.M.Suhoski,. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 106:3360–3365.
12. C.A.Chambers, J.P.Allison. 1997. Co-stimulation in T cell responses. Curr Opin Immunol. 9:396–404.
13. + T cells leads to enhanced and sustained anti-tumor effector functioning. Cytotherapy. 9:771–784.
14. A.A.Chekmasova, T.D.Rao, Y.Nikhamin, K.J.Park, D.A.Levine, D.R.Spriggs, R.J.Brentjens. 2010. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 16:3594–3606.
15. L.Chen. 2004. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat Rev Immunol. 4:336–347.
16. L.Chen, D.B.Flies. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 13:227–242.
17. M.Chmielewski, C.Kopecky, A.A.Hombach, H.Abken. 2011. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706.
18. J.Chu, Y.Deng, D.Benson, S.He, T.Hughes, J.Zhang,. 2014. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 28:917–927.
19. M.Croft. 2005. The evolving crosstalk between co-stimulatory and co-inhibitory receptors:HVEM–BTLA. Trends Immunol. 26:292–294.
20. T.J.Curiel, G.Coukos, L.Zou, X.Alvarez, P.Cheng, P.Mottram,. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949.
21. P.K.Darcy, M.H.Kershaw, J.A.Trapani, M.J.Smyth. 1998. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol. 28:1663–1672.
22. A.Di Stasi, B.De Angelis, C.M.Rooney, L.Zhang, A.Mahendravada, A.E.Foster,. 2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 113:6392–6402.
23. D.M.Durrant, D.W.Metzger. 2010. IL-12 can alleviate Th17-mediated allergic lung inflammation through induction of pulmonary IL-10 expression. Mucosal Immunol. 3:301–311.
24. Z.Eshhar, T.Waks, G.Gross, D.G.Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 90:720–724.
25. D.Fenoglio, P.Traverso, A.Parodi, F.Kalli, M.Zanetti, G.Filaci. 2013. Generation of more effective cancer vaccines. Hum Vaccin Immunother. 9:2543–2547.
26. H.M.Finney, A.N.Akbar, A.D.Lawson. 2004. Activation of resting human primary T cells with chimeric receptors:costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol. 172:104–113.
27. L.Gattinoni, S.E.Finkelstein, C.A.Klebanoff, P.A.Antony, D.C.Palmer, P.J.Spiess,. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. J Exp Med. 202:907–912.
28. S.Gill, S.K.Tasian, M.Ruella, O.Shestova, Y.Li, D.L.Porter,. 2014. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood. 123:2343–2354.
29. O.Goldberger, I.Volovitz, A.Machlenkin, E.Vadai, E.Tzehoval, L.Eisenbach. 2008. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res. 68:3450–3457.
30. M.C.Gong, J.-B.Latouche, A.Krause, W.D.Heston, N.H.Bander, M.Sadelain. 1999. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1:123.
31. L.Gorelik, R.A.Flavell. 2002. Transforming growth factor-β in T-cell biology. Nat Rev Immunol. 2:46–53.
32. Z.Grada, M.Hegde, T.Byrd, D.R.Shaffer, A.Ghazi, V.S.Brawley,. 2013. TanCAR:a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2:e105.
33. G.Gross, T.Waks, Z.Eshhar. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028.
34. J.A.Grossi, D.H.Raulet, J.P.Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356:607–609.
35. N.M.Haynes, M.B.Snook, J.A.Trapani, L.Cerruti, S.M.Jane, M.J.Smyth, P.K.Darcy. 2001. Redirecting mouse CTL against colon carcinoma:superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcεRI-γ. J Immunol. 166:182–187.
36. N.M.Haynes, J.A.Trapani, M.W.Teng, J.T.Jackson, L.Cerruti, S.M.Jane,. 2002. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 169:5780–5786.
37. C.Heuser, A.Hombach, C.Lösch, K.Manista, H.Abken. 2003. T-cell activation by recombinant immunoreceptors:impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther. 10:1408–1419.
38. D.Hollyman, J.Stefanski, M.Przybylowski, S.Bartido, O.Borquez-Ojeda, C.Taylor,. 2009. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 32:169.
39. A.Hombach, C.Heuser, R.Sircar, T.Tillmann, V.Diehl, W.Kruis,. 1997. T cell targeting of TAG72 + tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology. 113:1163–1170.
40. A.Hombach, C.Schneider, D.Sent, D.Koch, R.A.Willemsen, V.Diehl,. 2000. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer. 88:115–120.
41. A.Hombach, D.Sent, C.Schneider, C.Heuser, D.Koch, C.Pohl,. 2001a. T-Cell activation by recombinant receptors cd28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res. 61:1976–1982.
42. A.Hombach, A.Wieczarkowiecz, T.Marquardt, C.Heuser, L.Usai, C.Pohl,. 2001b. Tumor-specific T cell activation by recombinant immunoreceptors:CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol. 167:6123–6131.
43. M.Hosseini, M.Haji-Fatahaliha, F.Jadidi-Niaragh, J.Majidi, M.Yousefi. 2015. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 1–11.
44. Z.Hu, J.Xia, J.Wargo, Y.-G.Yang. 2013. Generation of human T cells expressing only the engineered tumor antigen specific TCR in humanized mice for preclinical research and anticancer therapy (P4364). J Immunol. 190:177.15.
45. M.Hudecek, M.-T.Lupo-Stanghellini, P.L.Kosasih, D.Sommermeyer, M.C.Jensen, C.Rader, S.R.Riddell. 2013. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 19:3153–3164.
46. M.Hudecek, T.M.Schmitt, S.Baskar, M.T.Lupo-Stanghellini, T.Nishida, T.N.Yamamoto,. 2010. The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1- specific chimeric antigen receptor. Blood. 116:4532–4541.
47. P.Hwu, G.Shafer, J.Treisman, D.Schindler, G.Gross, R.Cowherd,. 1993. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 178:361–366.
48. C.A.Jacobson, J.Ritz. 2011. Time to put the CAR-T before the horse. Blood. 118:4761–4762.
49. S.C.Jameson, D.Masopust. 2009. Diversity in T cell memory:an embarrassment of riches. Immunity. 31:859–871.
50. B.Jena, S.Maiti, H.Huls, H.Singh, D.A.Lee, R.E.Champlin, L.J.Cooper. 2013. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PloS one. 8:e57838.
51. M.C.Jensen, L.Popplewell, L.J.Cooper, D.Digiusto, M.Kalos, J.R.Ostberg, S.J.Forman. 2010. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19- specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 16:1245–1256.
52. C.H.June. 2007. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 117:1466–1476.
53. K.S.Kahlon, C.Brown, L.J.Cooper, A.Raubitschek, S.J.Forman, M.C.Jensen. 2004. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64:9160–9166.
54. S.Kailayangiri, B.Altvater, J.Meltzer, S.Pscherer, A.Luecke, C.Dierkes,. 2012. The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 106:1123–1133.
55. M.Kalos, B.L.Levine, D.L.Porter, S.Katz, S.A.Grupp, A.Bagg, C.H.June. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 3:95ra73.
56. S.C.Katz, R.A.Burga, E.Mccormack, L.J.Wang, J.W.Mooring, G.Point,. 2015. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 1421.2014.
57. T.Kazemi, V.Younesi, F.Jadidi-Niaragh, M.Yousefi. 2015. Immunotherapeutic approaches for cancer therapy:an updated review. Artif Cells Nanomed Biotechnol. 1–11.
58. S.P.Kerkar, R.S.Goldszmid, P.Muranski, D.Chinnasamy, Z.Yu, R.N.Reger,. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 121:4746.
59. S.P.Kerkar, P.Muranski, A.Kaiser, A.Boni, L.Sanchez-Perez, Z.Yu,. 2010. Tumor-specific CD8 + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70:6725–6734.
60. M.H.Kershaw, G.Wang, J.A.Westwood, R.K.Pachynski, H.L.Tiffany, F.M.Marincola,. 2002. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 13:1971–1980.
61. M.H.Kershaw, J.A.Westwood, L.L.Parker, G.Wang, Z.Eshhar, S.A.Mavroukakis,. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 12:6106–6115.
62. J.N.Kochenderfer, M.E.Dudley, S.A.Feldman, W.H.Wilson, D.E.Spaner, I.Maric,. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood. 119:2709–2720.
63. J.N.Kochenderfer, M.E.Dudley, S.H.Kassim, R.P.Somerville, R.O.Carpenter, M.Stetler-Stevenson,. 2014. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33:540–549.
64. J.N.Kochenderfer, S.A.Feldman, Y.Zhao, H.Xu, M.A.Black, R.A.Morgan,. 2009. Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. J Immunother. 32:689.
65. J.N.Kochenderfer, W.H.Wilson, J.E.Janik, M.E.Dudley, M.Stetler- Stevenson, S.A.Feldman,. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116:4099–4102.
66. H.Koehler, D.Kofler, A.Hombach, H.Abken. 2007. CD28 Costimulation Overcomes Transforming Growth Factor-β–Mediated Repression of Proliferation of Redirected Human CD4+ and CD8+ T Cells in an Antitumor Cell Attack. Cancer Res. 67:2265–2273.
67. M.Koneru, T.J.Purdon, D.Spriggs, S.Koneru, R.J.Brentjens. 2015. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 4:e994446.
68. C.M.Kowolik, M.S.Topp, S.Gonzalez, T.Pfeiffer, S.Olivares, N.Gonzalez,. 2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66:10995–11004.
69. P.Kvistborg, C.J.Shu, B.Heemskerk, M.Fankhauser, C.A.Thrue, M.Toebes,. 2012. TIL therapy broadens the tumor-reactive CD8 + T cell compartment in melanoma patients. Oncoimmunology. 1:409–418.
70. N.Ladygina, S.Gottipati, K.Ngo, G.Castro, J.Y.Ma, H.Banie,. 2013. PI3Kγ kinase activity is required for optimal T-cell activation and differentiation. Eur J Immunol. 43:3183–3196.
71. C.H.Lamers, J.W.Gratama, S.O.Warnaar, G.Stoter, R.L.Bolhuis. 1995. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer. 60:450–457.
72. C.H.Lamers, S.Sleijfer, A.G.Vulto, W.H.Kruit, M.Kliffen, R.Debets,. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX:first clinical experience. J Clin Oncol. 24:e20–e22.
73. C.H.Lamers, R.Willemsen, P.Van Elzakker, S.Van Steenbergen-Langeveld, M.Broertjes, J.Oosterwijk-Wakka,. 2011. Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells. Blood. 117:72–82.
74. J.C.Lee, E.Hayman, H.J.Pegram, E.Santos, G.Heller, M.Sadelain, R.Brentjens. 2011. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71:2871–2881.
75. D.J.Lenschow, T.L.Walunas, J.A.Bluestone. 1996. CD28/B7 system of T cell costimulation. Ann Rev Immunol. 14:233–258.
76. A.Loskog, V.Giandomenico, C.Rossig, M.Pule, G.Dotti, M.Brenner. 2006. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 20:1819–1828.
77. C.U.Louis, B.Savoldo, G.Dotti, M.Pule, E.Yvon, G.D.Myers,. 2011. Antitumor activity and long-term fate of chimeric antigen receptor– positive T cells in patients with neuroblastoma. Blood. 118:6050–6056.
78. J.Maher, R.J.Brentjens, G.Gunset, I.Rivière, M.Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol. 20:70–75.
79. D.Mezzanzanica, S.Canevari, A.Mazzoni, M.Figini, M.I.Colnaghi, T.Waks,. 1997. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 5:401–407.
80. R.A.Morgan, N.Chinnasamy, D.Abate-Daga, A.Gros, P.F.Robbins, Z.Zheng,. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36:133–151.
81. R.A.Morgan, J.C.Yang, M.Kitano, M.E.Dudley, C.M.Laurencot, S.A.Rosenberg. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851.
82. A.Muniappan, B.Banapour, J.Lebkowski, S.Talib. 2000. Ligand- mediated cytolysis of tumor cells:use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 7:128–134.
83. P.Muranski, A.Boni, C.Wrzesinski, D.E.Citrin, S.A.Rosenberg, R.Childs, N.P.Restifo. 2006. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol. 3:668–681.
84. A.Murphy, J.Westwood, L.Brown, M.Teng, M.Moeller, Y.Xu,. 2007. Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther. 14:499–508.
85. T.I.Näslund, U.Gehrmann, K.R.Qazi, M.C.Karlsson, S.Gabrielsson. 2013. Dendritic cell–derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol. 190:2712–2719.
86. T.M.Niederman, Z.Ghogawala, B.S.Carter, H.S.Tompkins, M.M.Russell, R.C.Mulligan. 2002. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA. 99:7009–7014.
87. C.Pameijer, A.Navanjo, B.Meechoovet, J.Wagner, B.Aguilar, C.Wright,. 2007. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 14:91–97.
88. A.C.Parente-Pereira, J.Burnet, D.Ellison, J.Foster, D.M.Davies, S.Van Der Stegen,. 2011. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol. 31:710–718.
89. J.R.Park, D.L.Digiusto, M.Slovak, C.Wright, A.Naranjo, J.Wagner,. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 15:825–833.
90. H.J.Pegram, J.C.Lee, E.G.Hayman, G.H.Imperato, T.F.Tedder, M.Sadelain, R.J.Brentjens. 2012. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119:4133–4141.
91. F.Perosa, E.Favoino, M.A.Caragnano, M.Prete, F.Dammacco. 2005. CD20:a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 4:526–531.
92. J.H.Pinthus, T.Waks, K.Kaufman-Francis, D.G.Schindler, A.Harmelin, H.Kanety, 2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63:2470–2476.
93. D.L.Porter, B.L.Levine, M.Kalos, A.Bagg, C.H.June. 2011. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 365:725–733.
94. M.-C.S.Pranchevicius, T.R.Vieira. 2013. Production of recombinant immunotherapeutics for anticancer treatment:The role of bioengineering. Bioengineered. 4:305–312.
95. M.Pritchard, S.Wolf, W.Kraybill, E.A.Repasky. 2005. The anti-tumor effect of interleukin-12 is enhanced by mild (fever-range) thermal therapy. Immunol Invest. 34:361–380.
96. M.A.Pule, B.Savoldo, G.D.Myers, C.Rossig, H.V.Russell, G.Dotti,. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors:persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 14:1264–1270.
97. M.A.Pulè, K.C.Straathof, G.Dotti, H.E.Heslop, C.M.Rooney, M.K.Brenner. 2005. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941.
98. G.A.Rabinovich, D.Gabrilovich, E.M.Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol. 25:267.
99. P.F.Robbins, M.E.Dudley, J.Wunderlich, M.El-Gamil, Y.F.Li, J.Zhou,. 2004. Cutting edge:persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 173:7125–7130.
100. S.A.Rosenberg, M.E.Dudley. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 21:233–240.
101. C.Rossig, C.M.Bollard, J.G.Nuchtern, C.M.Rooney, M.K.Brenner. 2002. Epstein-Barr virus–specific human T lymphocytes expressing antitumor chimeric T-cell receptors:potential for improved immunotherapy. Blood. 99:2009–2016.
102. J.S.Bridgeman, R.E.Hawkins, A.A.Hombach, H.Abken, D.E.Gilham. 2010. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther. 10:77–90.
103. M.Sadelain, I.Rivière, R.Brentjens. 2003. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 3:35–45.
104. E.B.Santos, R.Yeh, J.Lee, Y.Nikhamin, B.Punzalan, B.Punzalan,. 2009. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 15:338–344.
105. B.Savoldo, C.A.Ramos, E.Liu, M.P.Mims, M.J.Keating, G.Carrum,. 2011. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. J Clin Invest. 121:1822.
106. R.D.Schreiber, L.J.Old, M.J.Smyth. 2011. Cancer immunoediting:integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570.
107. B.Seliger. 2008. Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol. 5:361–367.
108. Z.Sharifzadeh, F.Rahbarizadeh, M.A.Shokrgozar, D.Ahmadvand, F.Mahboudi, F.R.Jamnani, S.M.Moghimi. 2013. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 334:237–244.
109. J.E.Smith-Garvin, G.A.Koretzky, M.S.Jordan. 2009. T cell activation. Ann Rev Immunol. 27:591–619.
110. P.Spear, A.Barber, A.Rynda-Apple, C.L.Sentman. 2012. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol. 188:6389–6398.
111. G.Stewart-Jones, A.Wadle, A.Hombach, E.Shenderov, G.Held, E.Fischer,. 2009. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA. 106:5784–5788.
112. J.Sun, G.Dotti, L.E.Huye, A.E.Foster, B.Savoldo, M.M.Gramatges,. 2010. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther. 18:2006–2017.
113. K.Tamada, D.Geng, Y.Sakoda, N.Bansal, R.Srivastava, Z.Li, E.Davila. 2012. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 18:6436–6445.
114. D.Tassev, M.Cheng, N.-K.Cheung. 2012. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 19:84–100.
115. M.W.Teng, M.H.Kershaw, M.Moeller, M.J.Smyth, P.K.Darcy. 2004. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther. 15:699–708.
116. B.G.Till, M.C.Jensen, J.Wang, E.Y.Chen, B.L.Wood, H.A.Greisman,. 2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112:2261–2271.
117. B.G.Till, M.C.Jensen, J.Wang, X.Qian, A.K.Gopal, D.G.Maloney,. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4–1BB domains:pilot clinical trial results. Blood. 119:3940–3950.
118. ™ in Oncogenesis. 18.
119. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.Mcdermott,. 2012. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 366:2443–2454.
120. G.Trinchieri, S.Pflanz, R.A.Kastelein. 2003. The IL-12 family of heterodimeric cytokines:new players in the regulation of T cell responses. Immunity. 19:641–644.
121. K.Urbanska, E.Lanitis, M.Poussin, R.C.Lynn, B.P.Gavin, S.Kelderman,. 2012. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72:1844–1852.
122. J.Vera, B.Savoldo, S.Vigouroux, E.Biagi, M.Pule, C.Rossig,. 2006. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 108:3890–3897.
123. J.Wang, M.Jensen, Y.Lin, X.Sui, E.Chen, C.G.Lindgren,. 2007. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 18:712–725.
124. J.Wang, O.W.Press, C.G.Lindgren, P.Greenberg, S.Riddell, X.Qian,. 2004. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8 + cytotoxic T lymphocytes. Mol Ther. 9:577–586.
125. J.A.Westwood, M.J.Smyth, M.W.Teng, M.Moeller, J.A.Trapani, A.M.Scott,. 2005. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA. 102:19051–19056.
126. L.Zhang, S.P.Kerkar, Z.Yu, Z.Zheng, S.Yang, N.P.Restifo,. 2011. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 19:751–759.
127. Y.Zhao, Q.J.Wang, S.Yang, J.N.Kochenderfer, Z.Zheng, X.Zhong,. 2009. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 183:5563–5574.
128. X.-S.Zhong, M.Matsushita, J.Plotkin, I.Riviere, M.Sadelain. 2010. Chimeric Antigen Receptors Combining 4–1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8 & plus; T Cell–mediated Tumor Eradication. Mol Ther. 18:413–420.
129. Y.Zou, P.Stastny, C.Süsal, B.Döhler, G.Opelz. 2007. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 357:1293–1300.